Powder: -20°C for 3 years | In solvent: -80°C for 1 year
A 438079 is a potent, and selective antagonist of P2X7 receptor (pIC50: 6.9).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 9,500 | |||
5 mg | 在庫あり | ¥ 15,500 | |||
10 mg | 在庫あり | ¥ 22,500 | |||
25 mg | 在庫あり | ¥ 43,500 | |||
50 mg | 在庫あり | ¥ 72,000 | |||
100 mg | 在庫あり | ¥ 127,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 20,500 |
説明 | A 438079 is a potent, and selective antagonist of P2X7 receptor (pIC50: 6.9). |
ターゲット&IC50 | P2X7 receptor:6.9(pIC50) |
In vitro | A 438079 blocks BzATP-(10 μM) evoked changes in intracellular calcium concentrations with an IC50 of 321 nM in 1321N1 cells stably expressing rat P2X7 receptors. A 438079 is also selective for the P2X7 receptor, at concentrations up to 100 μM[1]. |
In vivo | In neuropathic rats noxious and innocuous evoked activity of different classes of spinal neurons is reduced by A 438079 (80 μmol/kg, i.v.), and it significantly raises withdrawal thresh-olds in both the SNL and CCI models[1]. A 438079 has superior neuroprotective effects compared with an equal dose of phenobarbital (25 mg/kg)[2]. A 438079 partially but significantly prevents the 6-OHDA-induced depletion of striatal DA stores[3]. Pretreatment with A 438079 reduces nociceptive behavior scores in the HC model[4]. |
キナーゼ試験 | Human astrocytoma cells, 1321N1, are grown to stably express rat P2X7, human P2X4, P2X2a, P2X2/3, P2X1, P2Y1 and P2Y2 recombinant receptors. Agonist, BzATP, 2,3-O-(4-ben-zoylbenzoyl)-ATP or ATP-induced changes in intracellular Ca2+ concentrations are assessed in all of the cell lines using the Ca2+ chelating dye, Fluo-4, in conjunction with a Fluorometric Imaging Plate Reader. The cells are plated out the day before the experiment onto poly-D-lysine-coated black 96 well plates. After the agonist addition, changes in intracellular Ca2+ concentrations are recorded, per second, for 3 min. Ligands are tested at 11 half-log concentrations from 0.1nM to 100 μM. BzATP or ATP concentrations corresponds to the EC70 values for each receptor to enable comparison of antagonist potencies across the multiple P2 receptor subtypes. A 438079 is added to the cell plate and ?uorescence data are collected for 3 min before the addition of agonist, subsequently, data are then collected for another 2 min. The pEC50 or pIC50 values are derived from a single curve ?t [1]. |
動物実験 | To confirm A 438079 reach the brain after systemic administration, P10 rat pups are injected with 5 mg/kg A 438079 and killed either 10 min, 30 min, or 2 h later (n=4 per group). Blood samples are centrifuged at 1000×g for 10 min to isolate the plasma. Samples are analyzed using LC-MS/MS by a service provider. Briefly, protein is precipitated from 50 μL aliquots of the individual plasma or brain tissue homogenate, and A 438079 is quantified by LC-MS/MS from a five-point standard curve [2]. |
分子量 | 306.15 |
分子式 | C13H9Cl2N5 |
CAS No. | 899507-36-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (326.64 mM), Sonication is recommended.
H2O: 0.2 mg/mL (0.65 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
A 438079 899507-36-9 Membrane transporter/Ion channel Neuroscience P2X Receptor Inhibitor inhibit P2XRs A438079 A-438079 inhibitor